SG52806A1 - Interferon solution - Google Patents

Interferon solution

Info

Publication number
SG52806A1
SG52806A1 SG1996010030A SG1996010030A SG52806A1 SG 52806 A1 SG52806 A1 SG 52806A1 SG 1996010030 A SG1996010030 A SG 1996010030A SG 1996010030 A SG1996010030 A SG 1996010030A SG 52806 A1 SG52806 A1 SG 52806A1
Authority
SG
Singapore
Prior art keywords
interferon solution
interferon
solution
Prior art date
Application number
SG1996010030A
Other languages
English (en)
Inventor
Guenter Gross
Sabino Del Terzo
Saran Kandakuri Kumar
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SG52806A1 publication Critical patent/SG52806A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Detergent Compositions (AREA)
SG1996010030A 1995-04-06 1996-04-03 Interferon solution SG52806A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP95105166 1995-04-06

Publications (1)

Publication Number Publication Date
SG52806A1 true SG52806A1 (en) 1998-09-28

Family

ID=8219166

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996010030A SG52806A1 (en) 1995-04-06 1996-04-03 Interferon solution

Country Status (32)

Country Link
US (1) US5762923A (fr)
EP (1) EP0736303B1 (fr)
JP (1) JP2758154B2 (fr)
KR (1) KR100212346B1 (fr)
CN (1) CN1066065C (fr)
AR (1) AR002932A1 (fr)
AT (1) ATE183650T1 (fr)
AU (1) AU685356B2 (fr)
BR (1) BR9601276A (fr)
CA (1) CA2172664C (fr)
CO (1) CO4750807A1 (fr)
CY (1) CY2194B1 (fr)
CZ (1) CZ287626B6 (fr)
DE (1) DE69603894T2 (fr)
DK (1) DK0736303T3 (fr)
ES (1) ES2136910T3 (fr)
GR (1) GR3031775T3 (fr)
HK (1) HK1012232A1 (fr)
HU (1) HU227643B1 (fr)
IL (1) IL117752A (fr)
MA (1) MA23838A1 (fr)
MY (1) MY113594A (fr)
NO (1) NO316801B1 (fr)
NZ (1) NZ286300A (fr)
PE (1) PE38897A1 (fr)
PL (1) PL183873B1 (fr)
RU (1) RU2113845C1 (fr)
SA (1) SA96160728B1 (fr)
SG (1) SG52806A1 (fr)
TR (1) TR199600287A2 (fr)
TW (1) TW426523B (fr)
ZA (1) ZA962553B (fr)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
ES2224290T5 (es) * 1996-12-24 2012-03-12 Biogen Idec Ma Inc. Formulaciones l�?quidas estables de interferón.
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
ID28470A (id) * 1998-03-26 2001-05-24 Schering Corp Formulasi-formulasi untuk perlindungan terhadap konjugasi polietilen glikol-interferon alfa
US6180096B1 (en) 1998-03-26 2001-01-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
DK1069912T3 (da) * 1998-04-03 2007-11-12 Novartis Vaccines & Diagnostic Injicerbare IGF-formuleringer, der indeholder succinat som puffermiddel
JP5281726B2 (ja) 1998-05-15 2013-09-04 メルク・シャープ・アンド・ドーム・コーポレーション 慢性Ｃ型肝炎感染を有する、抗ウイルス処置を受けていない患者における、リバビリンおよびインターフェロンαを含む併用療法
ATE307597T1 (de) * 1998-06-08 2005-11-15 Hoffmann La Roche Verwendung von peg-ifn-alpha und ribavirin zur behandlung chronischer hepatitis c
IL140984A0 (en) * 1998-07-23 2002-02-10 Lilly Co Eli Fsh and fsh variant formulations, products and methods
US20030166525A1 (en) 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
US6783965B1 (en) * 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
ATE498409T1 (de) 1998-08-06 2011-03-15 Mountain View Pharmaceuticals Peg-uricase konjugate und verwendung davon
JP2002532556A (ja) * 1998-12-22 2002-10-02 シェリング・コーポレーション Ｃ型肝炎ウイルス感染のインターロイキン−１０での処置
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
ATE419001T1 (de) 1999-04-08 2009-01-15 Schering Corp Melanoma therapie
US6923966B2 (en) * 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
US6362162B1 (en) 1999-04-08 2002-03-26 Schering Corporation CML Therapy
US6605273B2 (en) 1999-04-08 2003-08-12 Schering Corporation Renal cell carcinoma treatment
KR100399156B1 (ko) * 1999-11-19 2003-09-26 주식회사 엘지생명과학 α-인터페론의 용액제형
CN1175901C (zh) * 1999-12-06 2004-11-17 天津华立达生物工程有限公司 一种稳定的干扰素水溶液
CA2405557C (fr) 2000-04-12 2013-09-24 Human Genome Sciences, Inc. Proteines hybrides d'albumine
US7208167B2 (en) * 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
DE60139339D1 (de) 2000-11-07 2009-09-03 Novartis Vaccines & Diagnostic Stabilisierte interferonzusammensetzungen
CN1245215C (zh) 2001-02-28 2006-03-15 四川省生物工程研究中心 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
US8551469B2 (en) 2001-02-28 2013-10-08 Superlab Far East Limited Treatment of tumors and viral diseases with recombinant interferon alpha
JP2002265383A (ja) * 2001-03-14 2002-09-18 Mitsubishi Pharma Corp インターフェロンα注射用液状製剤
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
WO2002083165A1 (fr) * 2001-04-10 2002-10-24 Sumitomo Pharmaceuticals Co., Ltd. Preparations stables destinees a etre injectees
LT4947B (lt) 2001-09-26 2002-08-26 Biotechnologijos Institutas Interferono alfa farmacinė kompozicija
EP2261250B1 (fr) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. Protéines de fusion d'albumine et GCSF
KR20050012224A (ko) 2002-05-21 2005-01-31 다이이찌 산토리 파마 가부시키가이샤 그렐린 함유 의약 조성물
CA2518903C (fr) 2003-04-02 2013-02-05 Ares Trading S.A. Formulations pharmaceutiques fsh et lh
TWI272948B (en) * 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
AR044302A1 (es) * 2003-05-13 2005-09-07 Ares Trading Sa Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
ES2414705T3 (es) 2003-06-20 2013-07-22 Ares Trading S.A. Formulaciones liofilizadas de FSH/LH
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
AR045258A1 (es) * 2003-08-21 2005-10-19 Altana Pharma Ag Un producto farmaceutico para inyeccion
US7585647B2 (en) 2003-08-28 2009-09-08 Guangwen Wei Nucleic acid encoding recombinant interferon
JP4896745B2 (ja) 2004-02-02 2012-03-14 アンブレツクス・インコーポレイテツド 修飾されたヒトインターフェロンポリペプチドおよびこれらの使用
EA012205B1 (ru) 2004-05-17 2009-08-28 Арес Трейдинг С.А. Гидрогелевые препараты интерферона
WO2005117948A1 (fr) 2004-06-01 2005-12-15 Ares Trading S.A. Procede de stabilisation de proteines
CN1993139B (zh) * 2004-06-01 2011-02-16 阿雷斯贸易股份有限公司 稳定的干扰素液体制剂
US7632491B2 (en) 2004-08-12 2009-12-15 Schering Corporation Stable pegylated interferon formulation
JP4951344B2 (ja) * 2004-08-24 2012-06-13 第一三共株式会社 生理活性ペプチド液状製剤
WO2006110819A2 (fr) 2005-04-11 2006-10-19 Savient Pharmaceuticals, Inc. Formes variantes de l'urate oxydase et leur utilisation
ES2302402B1 (es) 2005-06-16 2009-05-08 Proyecto De Biomedicina Cima, S.L. Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa.
CA2618068C (fr) 2005-08-05 2016-02-16 Amgen Inc. Formulations pharmaceutiques de proteine aqueuse stable ou d'anticorps et leur preparation
CU23432B6 (es) 2005-11-02 2009-10-16 Ct Ingenieria Genetica Biotech Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
WO2008026044A2 (fr) * 2006-08-31 2008-03-06 Wockhardt Research Centre Compositions pharmaceutiques de bupropion
CN104524567A (zh) 2007-01-16 2015-04-22 阿布维公司 用于治疗银屑病的方法
WO2008145323A1 (fr) * 2007-05-31 2008-12-04 F. Hoffmann-La Roche Ag Formulation pharmaceutique comprenant des interférons
CN101636411B (zh) * 2007-09-04 2013-01-09 厦门伯赛基因转录技术有限公司 聚乙二醇修饰的干扰素α2a及其制备方法和应用
ES2382124T3 (es) * 2007-09-04 2012-06-05 Biosteed Gene Expression Tech. Co., Ltd. Interferón alfa 2b modificado con polietilenglicol y método de preparación y aplicaciones de este
US8216571B2 (en) * 2007-10-22 2012-07-10 Schering Corporation Fully human anti-VEGF antibodies and methods of using
PT2234645E (pt) 2007-12-20 2012-05-21 Merck Serono Sa Formulações de peg-interferão-beta
US20110293557A1 (en) 2008-06-13 2011-12-01 Proyecto De Biomedicina Cima, S.L. Conjugates for the administration of biologically active compounds
JP2012502906A (ja) * 2008-09-17 2012-02-02 ネクター セラピューティックス オリゴマー−プロテアーゼ阻害剤コンジュゲート
BRPI1010069A2 (pt) 2009-06-25 2016-03-15 Savient Pharmaceuticals Inc "método para prevenir reações à infusão durante terapia por uricase peguilada em pacientes; e método para diagnosticar se um paciente tratado com uricase peguilada desenvolverá reações à infusão ou desenvolverá liberação de uricase peguilada mediada por anticorpo sem a medição de títulos de anticorpos anti-peg e anti-uricase peguilada"
CN102101886A (zh) 2009-12-18 2011-06-22 四川辉阳生命工程股份有限公司 构象改变的重组干扰素晶体、其三维结构及应用
RU2447083C1 (ru) * 2010-07-20 2012-04-10 Закрытое Акционерное Общество "Биокад" НОВЫЙ ФУНКЦИОНАЛЬНО АКТИВНЫЙ ВЫСОКООЧИЩЕННЫЙ СТАБИЛЬНЫЙ КОНЪЮГАТ ИНТЕРФЕРОНА α С ПОЛИЭТИЛЕНГЛИКОЛЕМ, ПРЕДСТАВЛЕННЫЙ ОДНИМ ПОЗИЦИОННЫМ ИЗОМЕРОМ ПЭГ-NαH-ИФН, С УМЕНЬШЕННОЙ ИММУНОГЕННОСТЬЮ, С ПРОЛОНГИРОВАННЫМ БИОЛОГИЧЕСКИМ ДЕЙСТВИЕМ, ПРИГОДНЫЙ ДЛЯ МЕДИЦИНСКОГО ПРИМЕНЕНИЯ, И ИММУНОБИОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ
KR101303388B1 (ko) * 2010-10-26 2013-09-03 한미사이언스 주식회사 지속형 인터페론 알파 결합체의 액상 제제
CN102526758B (zh) * 2012-02-23 2013-02-13 北京三元基因工程有限公司 一种聚乙二醇化干扰素稳定的水溶液
TWI718086B (zh) 2013-01-07 2021-02-11 英屬維爾京群島商遠東超級實驗室有限公司 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物
US9388239B2 (en) 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
JP6445169B2 (ja) * 2014-09-23 2018-12-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ α型インターフェロンを含有する安定したベンジルアルコールフリーの水溶液製剤
RU2768656C1 (ru) * 2021-09-10 2022-03-24 Илья Александрович Марков Противовирусное средство в жидкой форме и способ его приготовления

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61277633A (ja) * 1985-05-31 1986-12-08 Toray Ind Inc インタ−フエロン組成物
EP0284249A1 (fr) * 1987-03-13 1988-09-28 Interferon Sciences, Inc. Composition lyophilisée de lymphokine
IL88233A (en) * 1987-11-03 1993-08-18 Genentech Inc Gamma interferon formulation
JPH0651642B2 (ja) * 1988-11-14 1994-07-06 大塚製薬株式会社 インターフェロン経鼻投与用製剤
WO1990005535A1 (fr) * 1988-11-14 1990-05-31 Otsuka Pharmaceutical Co., Ltd. Preparation a base d'interferon pour administration nasale
CA2033714A1 (fr) * 1990-01-25 1991-07-26 Alberto Ferro Preparations pharmaceutiques
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
IL109350A (en) * 1993-05-12 2001-01-28 Genentech Inc Stable liquid preparations of gamma interferon

Also Published As

Publication number Publication date
PL183873B1 (pl) 2002-07-31
TW426523B (en) 2001-03-21
IL117752A (en) 2000-11-21
GR3031775T3 (en) 2000-02-29
ES2136910T3 (es) 1999-12-01
RU2113845C1 (ru) 1998-06-27
AR002932A1 (es) 1998-05-27
CZ287626B6 (en) 2001-01-17
ATE183650T1 (de) 1999-09-15
MA23838A1 (fr) 1996-12-31
AU5044696A (en) 1996-10-17
JPH08283176A (ja) 1996-10-29
EP0736303A3 (fr) 1997-02-26
DE69603894D1 (de) 1999-09-30
AU685356B2 (en) 1998-01-15
DE69603894T2 (de) 2000-04-20
CN1141808A (zh) 1997-02-05
CO4750807A1 (es) 1999-03-31
NO961322D0 (no) 1996-04-01
US5762923A (en) 1998-06-09
JP2758154B2 (ja) 1998-05-28
CA2172664A1 (fr) 1996-10-07
CA2172664C (fr) 2000-10-03
KR960037063A (ko) 1996-11-19
PE38897A1 (es) 1997-10-04
CN1066065C (zh) 2001-05-23
CZ99496A3 (en) 1996-10-16
HK1012232A1 (en) 1999-07-30
CY2194B1 (en) 2002-11-08
MY113594A (en) 2002-04-30
HU227643B1 (en) 2011-10-28
SA96160728B1 (ar) 2005-05-04
HU9600857D0 (en) 1996-05-28
HUP9600857A2 (en) 1997-08-28
NO316801B1 (no) 2004-05-18
BR9601276A (pt) 1998-01-13
HUP9600857A3 (en) 1998-01-28
DK0736303T3 (da) 2000-01-10
EP0736303B1 (fr) 1999-08-25
TR199600287A2 (tr) 1997-03-21
KR100212346B1 (ko) 1999-08-02
PL313655A1 (en) 1996-10-14
EP0736303A2 (fr) 1996-10-09
NZ286300A (en) 1997-05-26
IL117752A0 (en) 1996-08-04
NO961322L (no) 1996-10-07
ZA962553B (en) 1996-10-07

Similar Documents

Publication Publication Date Title
ZA962553B (en) Interferon solution
DE59607964D1 (en) Oxymethoxy-3-aryl-pyron-derivate
DE59607241D1 (en) Endotracheal-tubus
ZA96206B (en) Chemically modified interferon
ZA968451B (en) Novel sulfonylaminopyrimidines
DE59605001D1 (en) Luftreinigungsgerät
DE59602888D1 (en) Breitstreckaggregat
DE59602283D1 (en) Inchbremseinrichtung
DE59602030D1 (en) Zellige polyurethan-elastomere
DE59505396D1 (en) Handhobelmaschine
DE59604506D1 (en) Rückkühlsystem
DE59600830D1 (en) Breitstrahldüse
DE59604913D1 (en) Carbonylverbindungen
CA76097S (en) Can
AU1105P (en) DALESE Metrosideros excelsus
MD881B1 (en) Apple-tree variety Focushor
MD868B1 (en) Apple-tree variety Sperantsa
AU125678S (en) Sandboard
AU126739S (en) Gamesboard
AU126766S (en) Gamesboard
AU126858S (en) Billycart
AU127251S (en) Sandboard
AU127800S (en) Gamesboard
AU128041S (en) Gamesboard
AU129378S (en) TeleChipper